DAIICHI SANKYO CO LTD

Explore how Daiichi Sankyo’s €1 billion German expansion and EMA approval of Datroway drive global oncology leadership and shareholder value.

FDA approves Daiichi Sankyo’s Datroway as first‑line therapy for triple‑negative breast cancer, boosting the company’s oncology profile and investor confidence.

Discover how Daiichi Sankyo’s FDA‑approved ENHERTU® with pertuzumab and AI‑driven biomarker work reshape HER2‑positive breast cancer treatment, boosting clinical and market prospects.

Daiichi Sankyo Co Ltd is facing a significant legal challenge from IHH Healthcare’s subsidiary, while also launching a collaborative initiative to advance lung cancer treatment.